Enteris BioPharma is looking to make some money on the side of its drug-delivery operation, opening a contract manufacturing facility and scouting for clients.
Catalent is investing in infrastructure again, spending to flesh out its European network of storage and packaging facilities in response to an increase in demand on the continent.
Charles River Laboratories' longtime chief financial officer is stepping down in a planned retirement, giving the preclinical CRO a chance to further integrate its recent acquisitions and increase its focus on drug discovery.
Months removed from a $150 million IPO, INC Research is looking to raise its profile among the world's largest CROs, inching toward the $1 billion annual revenue mark in the new year.
CRO giant Icon dialed up its fourth-quarter revenue on the way to a big year, forecasting another leap in 2015.
Global CRO Quintiles is planning to lay off about 270 workers, 1% of its payroll, in an effort to reduce "excess capacity," the company said.
Acquisitive Chinese CRO WuXi PharmaTech is borrowing up to $165 million to keep up its string of deals, eyeing investments in R&D and manufacturing.
CRO giant Parexel International has expanded its Rolodex of clinical trial sites to more than 180 around the world, a network the company says allows it to more quickly find patients for studies.
Theorem Clinical Research has signed a deal with Biomedical Systems to expands its testing services, enlisting a partner with expertise in diagnostics.
PRA Health Sciences, the latest CRO to go public, is expecting up to 10% revenue growth in 2015, hoping to top a transformational year that reshaped its business.
One of the world's largest CROs is no longer an independent entity as Covance has folded into testing giant LabCorp, closing a $6 billion deal and altering the industry landscape.
Actavis is selling its in-house R&D outsourcing company to private equity giant TPG, which has plans for more bolt-on acquisitions.
CRO giant inVentiv Health is opening an early-stage clinic in Miami, expanding its global Phase I services to the U.S. with an emphasis on complex studies.
Drug developer Catalent is reaping the benefits of an acquisitive 2014, boosting its revenue and profit in its first year after an IPO.
Marred by bad weather and an ongoing transition, contract drug developer AMRI swung to a loss in the fourth quarter, but steady gains in revenue have the company optimistic about the coming year.
After clearing roughly $4.2 billion in revenue in 2014, Quintiles is projecting another big year ahead, as the world's largest CRO counts on its backlog to keep business rolling in.
CRO giant Charles River Laboratories ended 2014 with a bang, boosting revenue by about 14% in the fourth quarter to close a deal-filled year.
Medidata has signed a deal with Garmin to integrate the company's wearable vitals monitor into its cloud-based data tracking technology.
Privately held BioClinica watched its eClinical sales jump 51% last year, the company said, reflecting a spike in Big Pharma's adoption of new trial technologies.
Quintiles founder Dennis Gillings is planning to step down from his role as chairman by the end of the year, endorsing the leadership of CEO Tom Pike and transitioning into a more advisory role at the world's largest CRO.